Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Asian participants ≥18 years of age at the time of initial Screening.~* Type 2 diabetes mellitus as per American Diabetes Association guidelines.~* Metformin monotherapy (≥1500 mg/day) with an initial Screening A1C of 7.0-10.5% (53-91 mmol/mol) OR metformin monotherapy (\<1500 mg/day) with an initial Screening A1C of 7.5-11.0% (58-97 mmol/mol) OR dual combination therapy with metformin + sulfonylurea, dipeptidyl peptidase-4 (DDP-4) inhibitor, meglitinide, or alpha-glucosidase inhibitor with an initial Screening A1C of 6.5-9.5% (48-80 mmol/mol).~* Body mass index (BMI) ≥18.0 kg/m\^2.~* Male or female not of reproductive potential.~* Female of reproductive potential who agrees to remain abstinent from heterosexual activity or to use 2 acceptable combinations of contraception.~Exclusion Criteria:~* History of type 1 diabetes mellitus or a history of ketoacidosis.~* History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant.)~* History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study start.~* Mean value for triplicate screening sitting systolic blood pressure \>160 mm Hg and/or diastolic blood pressure \>90 mm Hg after at least a 5-minute seated rest at screening~* Active, obstructive uropathy or indwelling urinary catheter.~* History of malignancy ≤5 years prior to study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.~* Routinely consumes \>2 alcoholic drinks per day or \>14 alcoholic drinks per week or engages in binge drinking.~* Any clinically significant malabsorption condition.~* Is on a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable prior to study start.~* Has undergone bariatric surgery within the past 12 months or \>12 months and is not weight stable prior to study start.~* A known hypersensitivity or intolerance to any sodium glucose co-transporter (SGLT2) inhibitor.~* On a previous clinical study with ertugliflozin.~* Is taking blood pressure or lipid altering medications that have not been on a stable dose for at least 4 weeks prior to study start.~* Current treatment for hyperthyroidism.~* Male participants with a serum creatinine \>=1.3 mg/dL (\>=115 mol/L) or female participants with a serum creatinine \>=1.2 mg/dL (\>=106 mol/L) or participants with an estimated glomerular filtration rate (eGFR) \<55 mL/min/1.73m\^2 according to the 4-variable Modification of Diet in Renal Disease (MDRD) equation at screening.~* An aspartate transaminase (AST) or alanine transaminase (ALT) \>2X the upper limit of normal (ULN) range at screening, or a total bilirubin \>1.5 X the ULN unless the participant has a history of Gilbert's.~* On thyroid replacement therapy and has not been on a stable dose for at least 6 weeks prior to study start.~* A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease.~* Has been treated with any of the following agents within 12 weeks of study start or during the pre-randomization period: Insulin of any type (except for short-term use during concomitant illness or other stress), other injectable anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), another SGLT2 inhibitor, bromocriptine, colesevelam, rosiglitazone or pioglitazone, or any other AHA with the exception of the protocol-approved agents.~* Is on or likely to require treatment ≥14 consecutive days or repeated courses of pharmacologic doses of corticosteroids.~* Has undergone a surgical procedure within 6 weeks prior to study start or has planned major surgery during the study.~* Pregnant or breast-feeding, or planning to conceive during the trial, including 14 days following the last dose of study medication.~* Planning to undergo hormonal therapy in preparation for egg donation during the trial, including 14 days following the last dose of study medication.~* Donated blood or blood products within 6 weeks of study start.~* Has Human Immunodeficiency Virus (HIV).~* Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells.~* Has clinically important hematological disorders (such as aplastic anemia, myeloproliferative or myelodyplastic syndromes, thrombocytopenia.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ertugliflozin 5 mg (Type: EXPERIMENTAL): Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
- Ertugliflozin 15 mg (Type: EXPERIMENTAL): Ertugliflozin 15 mg (ertugliflozin 5 mg + ertugliflozin 10 mg) administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.

Based on this trial design, predict the completion outcome and termination type (if applicable).